Data Show Promise of PRM-151 in Diseases Involving Fibrosis
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting
<0> The Yates NetworkKathryn Morris, 845-635-9828 </0>
, a biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that data from a clinical study of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF) will be presented in an oral presentation at the 2013 being held from May 17-22, 2013, in Philadelphia, Penn. The clinical data to be presented are from a randomized, double-blind, placebo controlled Phase 1b multiple ascending dose study which examined safety and tolerability, as well as exploratory efficacy endpoints.
Session Info: Mini Symposium, [D94] Interstitial Lung Disease: Innovative Therapies and Determinants of SurvivalDay/Date: Wednesday, May 22, 2013Session Time: 2:00 PM - 4:30 PMRoom 204 A-B (200 Level) Pennsylvania Convention CenterPresentation Title: A Phase I Study Of PRM-151 In Patients With Idiopathic Pulmonary Fibrosis,Authors: B. Van Den Blink, MD PhD, J. Burggraaf, MD, PhD, L.D. Morrison, MD, L.C. Ginns, MD, M.S. Wijsenbeek, MD, PhD, M. Moerland, PhD, M.R. Dillingh, MSc, M. Lupher, PhD
, Promedior’s lead product, is a recombinant form of an endogenous human protein, , that is specifically active at the site of tissue damage. PRM-151 is an agonist that acts as a macrophage differentiation factor to prevent and potentially reverse fibrosis. PRM-151 has shown broad anti-fibrotic activity in multiple preclinical models of fibrotic disease, including pulmonary fibrosis, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration.
Promedior has been granted Orphan Drug Designation for PRM-151 in IPF by the FDA in the United States and by the European Commission. A Phase 1a clinical study in healthy subjects and IPF patients demonstrated that PRM-151 was safe and well tolerated. A Phase 2 study in myelofibrosis patients is planned for initiation later this year.
is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving . Fibrosis is a harmful process that , when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon , an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, potentially preventing and reversing fibrosis.
Promedior has successfully advanced their in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit .